MST Access has published a research report on Lumos Diagnostics Limited (ASX: LDX).
The report considers Lumos’ business, recent clinical and commercial progress, and the commercialisation of FebriDx® in the United States.
Disclosure: MST Access prepared this report for Lumos Diagnostics. MST Access has also provided capital raising advisory services to Lumos Diagnostics within the past 12 months. The report contains MST Access’s own views, estimates and opinions and is not endorsed, adopted or verified by Lumos Diagnostics. Please read the full report, including its disclosures and disclaimers.
